NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025
NKGen Biotech (OTC: NKGN) announced its upcoming presentation at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto, Canada from July 27-31, 2025. The company will present a poster detailing the mechanism of action of troculeucel, their enhanced non-genetically modified NK cell therapy for Alzheimer's disease.
The presentation by Dr. Paul Y. Song will take place on Sunday, July 27, 2025, from 7:30 AM to 4:15 PM ET in the Exhibit Hall. The poster will include Phase I biomarker data and will be available on NKGen's website after the presentation.
NKGen Biotech (OTC: NKGN) ha annunciato la sua prossima presentazione alla Alzheimer's Association International Conference (AAIC) 2025 che si terrà a Toronto, Canada, dal 27 al 31 luglio 2025. L'azienda presenterà un poster che illustra il meccanismo d'azione di troculeucel, la loro terapia potenziata con cellule NK non modificate geneticamente per il trattamento della malattia di Alzheimer.
La presentazione del dott. Paul Y. Song si svolgerà domenica 27 luglio 2025, dalle 7:30 alle 16:15 ET nella Exhibit Hall. Il poster includerà dati sui biomarcatori di Fase I e sarà disponibile sul sito web di NKGen dopo la presentazione.
NKGen Biotech (OTC: NKGN) anunció su próxima presentación en la Conferencia Internacional de la Asociación de Alzheimer (AAIC) 2025 en Toronto, Canadá, del 27 al 31 de julio de 2025. La compañía presentará un póster que detalla el mecanismo de acción de troculeucel, su terapia mejorada con células NK no modificadas genéticamente para la enfermedad de Alzheimer.
La presentación del Dr. Paul Y. Song tendrá lugar el domingo 27 de julio de 2025, de 7:30 a.m. a 4:15 p.m. ET en la Exhibit Hall. El póster incluirá datos de biomarcadores de la Fase I y estará disponible en el sitio web de NKGen después de la presentación.
NKGen Biotech (OTC: NKGN)는 2025년 7월 27일부터 31일까지 캐나다 토론토에서 열리는 알츠하이머 협회 국제 학술대회(AAIC) 2025에서 발표할 예정임을 발표했습니다. 회사는 알츠하이머병 치료를 위한 비유전자 변형 NK 세포 치료제인 troculeucel의 작용 기전을 자세히 설명하는 포스터를 발표할 것입니다.
Paul Y. Song 박사의 발표는 2025년 7월 27일 일요일 동부 표준시 기준 오전 7시 30분부터 오후 4시 15분까지 전시홀에서 진행됩니다. 포스터에는 1상 바이오마커 데이터가 포함되며 발표 후 NKGen 웹사이트에서 확인할 수 있습니다.
NKGen Biotech (OTC : NKGN) a annoncé sa prochaine présentation lors de la Conférence Internationale de l'Association Alzheimer (AAIC) 2025 à Toronto, Canada, du 27 au 31 juillet 2025. L'entreprise présentera un poster détaillant le mécanisme d'action de troculeucel, leur thérapie améliorée par cellules NK non génétiquement modifiées pour la maladie d'Alzheimer.
La présentation du Dr Paul Y. Song aura lieu le dimanche 27 juillet 2025, de 7h30 à 16h15 ET dans le hall d'exposition. Le poster inclura des données sur les biomarqueurs de phase I et sera disponible sur le site web de NKGen après la présentation.
NKGen Biotech (OTC: NKGN) hat seine bevorstehende Präsentation auf der Alzheimer's Association International Conference (AAIC) 2025 angekündigt, die vom 27. bis 31. Juli 2025 in Toronto, Kanada, stattfindet. Das Unternehmen wird ein Poster vorstellen, das den Wirkmechanismus von troculeucel beschreibt, ihrer verbesserten, nicht genetisch veränderten NK-Zelltherapie für Alzheimer.
Die Präsentation von Dr. Paul Y. Song findet am Sonntag, den 27. Juli 2025, von 7:30 bis 16:15 Uhr ET in der Ausstellungshalle statt. Das Poster wird Phase-I-Biomarkerdaten enthalten und nach der Präsentation auf der Website von NKGen verfügbar sein.
- None.
- None.
SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Association International Conference 2025 (“AAIC 2025”) to be held in Toronto, Canada and online from July 27-31, 2025.
Presentation details are as follows:
| Poster Title: | Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer’s Disease Confirmed by Corresponding Phase I Biomarker Data. |
| Presenting Author: | Paul Y. Song, M.D. |
| Session Type: | Poster |
| Session Title: | Drug Development: Human |
| Session Time: | Sunday, July 27, 2025; 7:30 AM – 4:15 PM ET |
| Poster Board Number: | #101711 |
| Location: | Exhibit Hall |
More information about AAIC 2025 can be found at: https://aaic.alz.org/.
A copy of the poster will be available on the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/ once the poster presentation has concluded. Previously disclosed Phase 1 data on the positive effects of troculeucel on amyloid, tau, and neuroinflammation biomarkers in Alzheimer’s patients, which may not be included in this poster presentation, can also be found on the Scientific Publications webpage.
About Troculeucel
Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit https://nkgenbiotech.com/.
Forward-Looking Statements
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are patient to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:
Denise Chua, MBA, CLS, MLS(ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
External Contact:
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
When is NKGen Biotech (NKGN) presenting at AAIC 2025?
What will NKGen Biotech present about at AAIC 2025?
Who is presenting NKGen Biotech's research at AAIC 2025?
Where can investors find NKGen Biotech's AAIC 2025 presentation materials?
